The Food and Drug Administration is investigating whether convalescent plasma from recovered COVID-19 patients contains viable antibodies to treat SARS-CoV-2 in the sickest patients. While FDA trials continue, providers may request the plasma for investigational use in patients with the most serious and life-threatening COVID-19 infections. For more information, visit FDA.gov.

Related News Articles

Headline
The Department of Health and Human Services Assistant Secretary for Preparedness and Response has released a recording of its Sept. 24 webinar on strategies to…
Headline
A vast majority of nurse leaders (86%) feel prepared for a future COVID-19 surge, according to more than 1,800 nurse leaders the AHA’s American Organization…
Headline
The Food and Drug Administration yesterday posted updated comparative performance data for molecular tests to diagnose the COVID-19 virus. Test developers,…
Headline
Beginning today, American hospitals can purchase Veklury (remdesivir) directly from the drug’s distributor, the Department of Health and Human Services…
Headline
The Department of Health and Human Services today announced the availability of $20 billion to hospital and providers through the third Provider Relief…
Headline
An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it…